Subscribe To
LXRX / U.S. FDA approves Lexicon Pharma's heart failure drug
LXRX News
By Zacks Investment Research
October 11, 2023
Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts
A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The more_horizontal
By The Motley Fool
October 10, 2023
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday
Lexicon just launched heart failure therapy Inpefa this year. The drug was approved by the FDA in May. more_horizontal
By Proactive Investors
October 10, 2023
Lexicon Pharmaceuticals shares rise on Express Scripts support for Inpefa heart drug
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares jumped 9% in Tuesday pre-market trading after it announced that its Inpefa heart failure drug has more_horizontal
By Seeking Alpha
August 3, 2023
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice Pr more_horizontal
By Zacks Investment Research
August 3, 2023
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares more_horizontal
By GlobeNewsWire
July 28, 2023
Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial re more_horizontal
By PennyStocks
June 15, 2023
Penny Stocks To Buy? 4 To Watch With Big News Now
Are you on the hunt for the next big thing? Ready to catch the wave before it crests? more_horizontal
By The Motley Fool
June 2, 2023
Why Lexicon Pharmaceuticals Stock Crashed This Week
With a new heart failure drug in hand, Lexicon Pharmaceuticals decided to raise capital this week, causing its shares to fall by double digits. The co more_horizontal